Blocc Chemistry: A New Paradigm for Molecular Innovation
Excelsior has reinvented the way molecules are built, making it a task that robots can do and AI can use. Instead of trying to wrap robots around traditional synthesis, we leverage blocc chemistry that is inherently automatable. Molecules are built by iteratively snapping carbon-carbon bonds together, analogous to how peptides or DNA are assembled in sequence. This paradigm shift enables machines to synthesize molecules reliably and repeatably, eliminating the bottleneck of handcrafted chemistry.
Creating a Chemistry Language Model: Bloccs = Tokens
We treat chemical building blocks like words in a sentence. Each of these smart bloccs is a molecular token that’s been pre-programmed to precisely connect with others in both the digital and physical worlds. Just as language models leverage word-based tokens to understand and create meaningful natural language, our platform leverages smart bloccs to understand and create impactful molecular functions.
It’s the first-ever machine-friendly chemistry for small molecule science.
AI can mix and match these bloccs to predict a compound’s properties and discover optimal solutions quickly and effectively
Impact
Faster Discovery, Scalable Production, Secure Supply Chains
Accelerated and Enhanced Molecular Discovery
Our process dramatically speeds up molecular discovery. By combining automated blocc chemistry and AI, the time to identify a promising new medicine, material, or any other type of impactful small molecule drops from years to months.
Beyond discovering new molecular functions faster, this speed first enables practical pursuit of higher-order molecular functions that push the boundaries of scientific knowledge.
One Process:
Discovery to Manufacturing
Our platform tightly integrates discovery and manufacturing in one end-to-end environment. The same processes used to generate the first milligrams of a new compound are designed for straightforward scale-up to kilogram-level production.
Strategic Resilience
Excelsior’s launch comes at a pivotal time for pharma and other industries racing to secure supply chains and reshore capabilities across discovery, development, and production. The United States’ overreliance on offshoring critical molecular supply chains represents a major strategic vulnerability. Excelsior makes it economically viable to manufacture critical molecules domestically—with the same modular synthetic process that discovers them.
